Background: The aim of the study was to longitudinally evaluate the association between MMP-2, MMP-9, TIMP-1 and chest radiological findings in COVID-19 patients. Methods: COVID-19 patients were evaluated based on their hospital admission (baseline) and three months after hospital discharge (T post) and were stratified into ARDS and non-ARDS groups. As a control group, healthy donors (HD) were enrolled. Results: At the baseline, compared to HD (n = 53), COVID-19 patients (n = 129) showed higher plasma levels of MMP-9 (p < 0.0001) and TIMP-1 (p < 0.0001) and the higher plasma activity of MMP-2 (p < 0.0001) and MMP-9 (p < 0.0001). In the ARDS group, higher plasma levels of MMP-9 (p = 0.0339) and TIMP-1 (p = 0.0044) and the plasma activity of MMP-2 (p = 0.0258) and MMP-9 (p = 0.0021) compared to non-ARDS was observed. A positive correlation between the plasma levels of TIMP-1 and chest computed tomography (CT) score (& rho; = 0.2302, p = 0.0160) was observed. At the T post, a reduction in plasma levels of TIMP-1 (p < 0.0001), whereas an increase in the plasma levels of MMP-9 was observed (p = 0.0088). Conclusions: The positive correlation between TIMP-1 with chest CT scores highlights its potential use as a marker of fibrotic burden. At T post, the increase in plasma levels of MMP-9 and the reduction in plasma levels of TIMP-1 suggested that inflammation and fibrosis resolution were still ongoing.
Tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) and pulmonary involvement in COVID-19 pneumonia / Zingaropoli, Maria Antonella; Latronico, Tiziana; Pasculli, Patrizia; Masci, Giorgio Maria; Merz, Roberta; Ciccone, Federica; Dominelli, Federica; Del Borgo, Cosmo; Lichtner, Miriam; Iafrate, Franco; Galardo, Gioacchino; Pugliese, Francesco; Panebianco, Valeria; Ricci, Paolo; Catalano, Carlo; Ciardi, Maria Rosa; Liuzzi, Grazia Maria; Mastroianni, Claudio Maria. - In: BIOMOLECULES. - ISSN 2218-273X. - 13:7(2023), pp. 1-18. [10.3390/biom13071040]
Tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) and pulmonary involvement in COVID-19 pneumonia
Zingaropoli, Maria Antonella
;Pasculli, Patrizia;Masci, Giorgio Maria;Ciccone, Federica;Dominelli, Federica;Lichtner, Miriam;Iafrate, Franco;Galardo, Gioacchino;Pugliese, Francesco;Panebianco, Valeria;Ricci, Paolo;Catalano, Carlo;Ciardi, Maria Rosa;Mastroianni, Claudio Maria
2023
Abstract
Background: The aim of the study was to longitudinally evaluate the association between MMP-2, MMP-9, TIMP-1 and chest radiological findings in COVID-19 patients. Methods: COVID-19 patients were evaluated based on their hospital admission (baseline) and three months after hospital discharge (T post) and were stratified into ARDS and non-ARDS groups. As a control group, healthy donors (HD) were enrolled. Results: At the baseline, compared to HD (n = 53), COVID-19 patients (n = 129) showed higher plasma levels of MMP-9 (p < 0.0001) and TIMP-1 (p < 0.0001) and the higher plasma activity of MMP-2 (p < 0.0001) and MMP-9 (p < 0.0001). In the ARDS group, higher plasma levels of MMP-9 (p = 0.0339) and TIMP-1 (p = 0.0044) and the plasma activity of MMP-2 (p = 0.0258) and MMP-9 (p = 0.0021) compared to non-ARDS was observed. A positive correlation between the plasma levels of TIMP-1 and chest computed tomography (CT) score (& rho; = 0.2302, p = 0.0160) was observed. At the T post, a reduction in plasma levels of TIMP-1 (p < 0.0001), whereas an increase in the plasma levels of MMP-9 was observed (p = 0.0088). Conclusions: The positive correlation between TIMP-1 with chest CT scores highlights its potential use as a marker of fibrotic burden. At T post, the increase in plasma levels of MMP-9 and the reduction in plasma levels of TIMP-1 suggested that inflammation and fibrosis resolution were still ongoing.File | Dimensione | Formato | |
---|---|---|---|
Zingaropoli_Tissue-inhibitor_2023.pdf
accesso aperto
Note: Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.81 MB
Formato
Adobe PDF
|
2.81 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.